Market Overview

Morgan Stanley Sees 2014 Guidance for Tenet Healthcare as Full of Puts and Takes

Related THC
Barron's Recap: The Volatility Lovers
Top 4 Mid-Cap Stocks In The Hospitals Industry With The Highest EPS Growth Forecast For Next Year Daily Round Up 10/2/15: PE, DM, PDVW, MTZ (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst Andrew Schenker reiterated an Equal-Weight rating on Tenet Healthcare (NYSE: THC).

In the report, Morgan Stanley noted, “THC issued FY14 Adj. EBITDA guidance of $1.8B to $1.9B including reform benefit of $50M to $100M. Guidance compares with MS est. and consensus of $1.94B and 1.96B, respectively. THC's forecast assumes pro-forma admissions growth of -2% to flat adj. admissions growth of -1% to +1% and VHS synergies of $50M-$100M. Separately, the company anticipates 1Q14 adj. EBITDA of $350M-$400M including $10M in EHR, this compares with MS and street at $434M and $447M, respectively.”

Tenet Healthcare closed on Monday at $48.33.

Latest Ratings for THC

Sep 2015JP MorganInitiates Coverage onNeutral
Sep 2015BarclaysInitiates Coverage onOverweight
Jun 2015Wells FargoUpgradesMarket PerformOutperform

View More Analyst Ratings for THC
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (THC)

Get Benzinga's Newsletters